Last updated: September 1, 2026
Lorlatinib, marketed by Pfizer as Lorbrena, is an oral third-generation ALK tyrosine kinase inhibitor for ALK-positive metastatic non-small-cell lung cancer. Its commercial position is strengthening because the CROWN trial showed durable progression-free survival and superior intracranial control versus crizotinib. Pfizer’s revenue growth depends on expansion in earlier treatment lines, sustained use after prior ALK inhibitors, and protection from generic competition through the early-to-mid 2030s.
What is lorlatinib and which market does it address?
Lorlatinib is a macrocyclic ALK and ROS1 inhibitor developed for tumors with ALK rearrangements and central nervous system involvement. Its primary commercial market is metastatic ALK-positive NSCLC, a molecularly defined segment representing approximately 3% to 7% of NSCLC cases.
| Attribute |
Lorlatinib |
| Brand |
Lorbrena |
| Active ingredient |
Lorlatinib |
| Manufacturer |
Pfizer |
| Drug class |
Third-generation ALK tyrosine kinase inhibitor |
| Primary indication |
ALK-positive metastatic NSCLC |
| Dosage form |
25 mg and 100 mg oral tablets |
| Standard adult dose |
100 mg once daily |
| U.S. approval |
November 2018 accelerated approval; regular approval in 2021 |
| Key competitor |
Alectinib, marketed as Alecensa by Roche |
| Other competitors |
Brigatinib, crizotinib, ensartinib |
| Main differentiation |
CNS penetration, activity against resistance mutations, durable systemic control |
Lorlatinib is used both in patients who have not received prior systemic therapy and in patients whose disease has progressed after earlier ALK inhibitors. The first-line indication is the principal source of long-term commercial value because it creates the largest treatment duration and patient pool.
How has Pfizer’s lorlatinib revenue developed?
Pfizer’s Lorbrena revenue has moved from a specialty oncology launch product to a larger growth asset. Public Pfizer reporting places annual product sales in the hundreds of millions of dollars, with growth supported by first-line adoption and increasing recognition of its CNS efficacy.
| Fiscal year |
Approximate Lorbrena revenue |
Commercial interpretation |
| 2019 |
About $100 million |
Early post-launch uptake |
| 2020 |
About $170 million |
Expansion in previously treated disease |
| 2021 |
About $250 million |
Broader regulatory use |
| 2022 |
About $330 million |
First-line adoption begins contributing |
| 2023 |
About $450 million |
CROWN data and guideline adoption support growth |
| 2024 |
Approximately $500 million to $600 million |
Continued penetration in ALK-positive first-line treatment |
The exact figure depends on Pfizer’s reporting period and foreign-exchange treatment. Pfizer reports Lorbrena as an individual product in its annual and quarterly disclosures, but the company does not provide a separate global breakdown of price, volume, and treatment-line mix in every filing (Pfizer, 2024).
The financial trajectory remains positive, but the product’s growth rate should moderate as first-line penetration rises. Lorlatinib’s addressable population is limited by the low prevalence of ALK-positive disease. Revenue expansion therefore depends more on market share, treatment duration, geographic access, and line-of-therapy migration than on broad epidemiological growth.
What clinical data support lorlatinib’s commercial position?
The strongest commercial asset is the five-year CROWN dataset. In previously untreated ALK-positive advanced NSCLC, lorlatinib produced markedly longer progression-free survival than crizotinib.
At five years, approximately 60% of patients receiving lorlatinib remained free of disease progression, compared with approximately 8% of patients receiving crizotinib. Median progression-free survival for lorlatinib had not been reached at the five-year analysis, while the crizotinib arm had a median of approximately nine months (Solomon et al., 2024).
The trial also showed strong intracranial activity. This matters because ALK-positive NSCLC has a high incidence of brain metastases, and CNS progression is a major driver of treatment change, radiation use, morbidity, and cost.
Why CNS penetration affects market share
Lorlatinib crosses the blood-brain barrier and retains activity against several ALK resistance mutations. Its value proposition is strongest in patients with:
- Baseline brain metastases
- High risk of CNS progression
- Acquired resistance to earlier ALK inhibitors
- Need for a single systemic therapy with intracranial activity
Alectinib remains the principal first-line competitor because it also has strong CNS activity, mature clinical adoption, and broad physician familiarity. Lorlatinib’s advantage is the depth and durability of the CROWN results. Its disadvantages include central nervous system adverse effects, hyperlipidemia, weight gain, edema, and potential drug-drug interactions.
How does lorlatinib compare with competing ALK inhibitors?
| Drug |
Company |
Commercial position |
Key strengths |
Key limitations |
| Lorlatinib |
Pfizer |
Premium third-generation ALK inhibitor |
Durable PFS, CNS control, resistance mutation coverage |
Neurocognitive and metabolic adverse effects |
| Alectinib |
Roche |
Major first-line standard |
Strong efficacy, CNS activity, extensive use |
Earlier-generation resistance can emerge |
| Brigatinib |
Takeda |
First-line and post-crizotinib option |
Durable systemic and CNS activity |
Early pulmonary toxicity risk |
| Crizotinib |
Pfizer |
Earlier-generation ALK inhibitor |
Historical standard, broad familiarity |
Inferior CNS durability and shorter PFS |
| Ensartinib |
Xcovery/Denali-related commercial interests |
Emerging competitor |
Designed for resistance and CNS activity |
Market access and launch execution remain material |
Lorlatinib is not competing in a general lung-cancer market. It competes for treatment decisions within a small biomarker-defined population. The relevant commercial question is whether oncologists select lorlatinib over alectinib at diagnosis, not whether lorlatinib replaces chemotherapy across all NSCLC.
When does lorlatinib lose exclusivity?
Lorlatinib’s U.S. market protection extends beyond the original five-year new chemical entity period through patents and pediatric exclusivity. The principal composition-of-matter and related patent protections are expected to delay conventional generic entry into the early-to-mid 2030s.
| Protection category |
Expected commercial impact |
| U.S. new chemical entity exclusivity |
Expired after the initial 2018 approval period |
| Composition and core compound patents |
Primary barrier to generic entry |
| Formulation and solid-state patents |
Potential secondary barriers |
| Method-of-use patents |
May restrict labeled indication claims but are less effective against unrestricted generic supply |
| Pediatric exclusivity |
May add six months to qualifying listed patent terms |
| International patents |
Duration varies by country, with some markets facing earlier loss of exclusivity |
The FDA Orange Book lists multiple patents for Lorbrena, including patents directed to lorlatinib compounds, pharmaceutical compositions, and therapeutic use. Public patent records associate Pfizer entities with the core lorlatinib patent estate. The most commercially important U.S. rights extend into approximately 2032 to 2035, depending on the patent, patent-term adjustment, and pediatric extension (U.S. Food and Drug Administration, 2024a; U.S. Patent and Trademark Office, 2024).
Patent expiry should not be treated as a single date. Generic applicants may challenge individual patents before the latest listed expiration, while Pfizer may rely on additional patents, regulatory exclusivity, or litigation settlements to delay launch.
What patents protect lorlatinib?
The lorlatinib estate has several layers of protection:
- Composition-of-matter patents covering the macrocyclic ALK inhibitor and related chemical compounds.
- Pharmaceutical composition patents covering oral dosage forms and excipient combinations.
- Process and manufacturing patents covering synthesis, purification, crystallization, or solid-state forms.
- Method-of-use patents covering treatment of ALK-positive cancer and specific treatment settings.
- Pediatric exclusivity attached to qualifying listed patents.
Composition patents generally have the highest practical value because they can block a generic product regardless of the generic manufacturer’s formulation design. Formulation, process, and method-of-use patents are more vulnerable to design-around strategies or label carve-outs.
How strong is the lorlatinib patent estate?
The estate is commercially strong because the drug has:
- A small-molecule composition patent position
- Multiple potential Orange Book-listed patents
- A high-value oncology indication
- A differentiated clinical profile
- Limited substitutability in patients with CNS disease or ALK resistance
Its vulnerability is that generic applicants can challenge patents through Paragraph IV certifications. A generic company does not need to invalidate every patent if it can avoid a claim, win on one key patent, or obtain a settlement permitting an earlier launch.
What is the FDA regulatory status of Lorbrena?
The FDA granted accelerated approval to lorlatinib in 2018 for ALK-positive metastatic NSCLC previously treated with crizotinib and at least one other ALK inhibitor, or with alectinib or ceritinib as the first ALK inhibitor. The FDA converted the approval to regular approval in 2021 based on confirmatory evidence.
The FDA later approved lorlatinib for first-line treatment of metastatic ALK-positive NSCLC. The current U.S. label includes warnings for central nervous system effects, hyperlipidemia, atrioventricular block, and interstitial lung disease or pneumonitis (FDA, 2024b).
Regulatory expansion into earlier-line use materially increased the commercial opportunity. First-line treatment produces longer exposure per patient and supports guideline positioning before resistance develops.
Which companies are challenging lorlatinib exclusivity?
Generic competition is likely to come from large generic manufacturers and specialist oncology suppliers after the core U.S. patents expire or are successfully challenged. Publicly disclosed commercial activity does not establish a confirmed approved generic launch date.
Potential challengers may include companies with established abbreviated new drug application capabilities in oncology, such as:
- Teva Pharmaceutical Industries
- Sandoz
- Viatris
- Sun Pharmaceutical Industries
- Dr. Reddy’s Laboratories
- Cipla
- Zydus Lifesciences
- Amneal Pharmaceuticals
A company’s ability to file an ANDA does not mean it has secured approval, prevailed in litigation, or obtained a launch right. The decisive evidence will be FDA approval, Paragraph IV litigation records, and any settlement terms disclosed in securities filings or court documents.
What generic entry risks exist for lorlatinib?
Base-case launch scenario
The base case is no material generic entry before the early 2030s, followed by limited competition when core composition patents expire or are invalidated. Pfizer could experience a rapid price decline after the first generic launch because oral oncology products are generally vulnerable to payer substitution.
Accelerated-entry scenario
An earlier launch could occur if a generic applicant succeeds in Paragraph IV litigation or reaches a settlement with Pfizer. In that case, the launch date could precede the latest Orange Book patent expiration.
Delayed-entry scenario
Entry could be delayed beyond the core patent date if Pfizer obtains enforceable protection for a solid form, manufacturing process, or additional clinically relevant use. Such protection is less robust than composition-of-matter protection and may not prevent all generic sales.
The commercial effect of generic entry depends on the number of approved suppliers. A sole generic may initially retain substantial pricing, while multiple suppliers can produce steep net-price erosion within several quarters.
Does lorlatinib face biosimilar risk?
Lorlatinib has no biosimilar risk because it is a chemically synthesized small molecule, not a biologic. Its competitive threat is conventional generic substitution under the ANDA pathway.
The absence of biosimilar complexity makes post-exclusivity erosion potentially faster than for injectable monoclonal antibodies. Generic manufacturers do not need to reproduce a biologic manufacturing process or conduct the same type of clinical comparability program required for biosimilars.
What patent litigation and settlement issues affect Lorbrena?
A Paragraph IV filing would typically trigger patent litigation under the Hatch-Waxman framework if Pfizer sues within the statutory period. The litigation could impose an automatic 30-month stay on FDA approval of the ANDA, subject to court rulings and statutory exceptions.
The most important litigation questions would be:
- Whether the challenged patent claims cover the generic’s active ingredient or product;
- Whether Pfizer’s composition claims survive validity challenges;
- Whether the generic applicant can use a Section viii label carve-out for method-of-use claims;
- Whether a settlement permits launch before the latest patent expiry;
- Whether the Federal Trade Commission reviews settlement terms for anticompetitive provisions.
No publicly established settlement date should be assumed without a filed agreement, court docket, or company disclosure. Patent litigation risk is a timing issue rather than a question of whether lorlatinib has a durable market during the current decade.
How do geographic markets affect lorlatinib revenue?
The United States is the highest-value market because of oncology pricing and early access to targeted therapies. Europe and Japan contribute meaningful volume but generally produce lower net pricing and face country-specific reimbursement controls.
| Region |
Market characteristic |
| United States |
Highest price, strong molecular testing, substantial patent value |
| Europe |
Centralized and national reimbursement negotiations; variable uptake |
| Japan |
High ALK testing and specialty oncology use; local pricing controls |
| China |
Large patient pool but lower net price and intense local competition |
| Emerging markets |
Access constrained by testing, reimbursement, and affordability |
China and other Asian markets can increase volume but do not necessarily translate into proportional revenue growth. Local generic or copy-product competition may also emerge earlier, depending on national patent enforcement and regulatory pathways.
What manufacturing and intellectual-property barriers protect lorlatinib?
Lorlatinib manufacturing requires controlled synthesis of a complex macrocyclic molecule, impurity management, crystallization, and reproducible tablet production. These requirements create technical barriers, but they are secondary to the composition patent.
Manufacturing patents can increase the cost and time required for generic development. They are less likely to block every generic if an alternative synthetic route is available. Pfizer’s strongest protection remains the underlying molecule and the clinical evidence supporting its use in ALK-positive NSCLC.
What is the long-term financial outlook for lorlatinib?
Lorbrena should remain a growth product through the late 2020s if Pfizer maintains first-line share against alectinib and converts the CROWN results into guideline and physician preference advantages. Revenue growth will likely moderate as:
- The ALK-positive population remains small;
- Alectinib retains strong first-line positioning;
- Ensartinib and other next-generation inhibitors enter the market;
- Payers pressure branded oncology pricing;
- Patients eventually progress or discontinue because of toxicity.
The product’s revenue ceiling is lower than that of broad-population oncology drugs, but its treatment duration and premium targeted-therapy pricing support attractive economics. A reasonable strategic view is that lorlatinib can remain a several-hundred-million-dollar global product before generic entry, with the principal downside concentrated in patent litigation, competitive displacement, and earlier-than-expected generic launch.
Key Takeaways
- Lorlatinib is Pfizer’s premium third-generation ALK inhibitor for metastatic ALK-positive NSCLC.
- Its commercial value is driven by durable first-line efficacy and strong CNS control.
- Pfizer’s Lorbrena revenue has grown from launch-stage sales to approximately $500 million to $600 million annually.
- Alectinib is the most important competitor; brigatinib and ensartinib add further pressure.
- The FDA granted regular approval after accelerated approval and expanded lorlatinib into first-line treatment.
- Lorlatinib has no biosimilar risk because it is a small molecule.
- U.S. patent protection is expected to extend into approximately 2032 to 2035, depending on the patent and applicable extensions.
- Paragraph IV litigation could move generic entry earlier than the latest listed patent expiry.
- The strongest patents are those covering the active compound; formulation and method-of-use patents provide secondary protection.
- Revenue should grow through the late 2020s but face a sharp erosion risk after the first approved generic launch.
FAQs About Lorlatinib Market and Exclusivity
What is the brand name of lorlatinib?
Lorlatinib is marketed by Pfizer under the brand name Lorbrena.
Is lorlatinib a first-line lung-cancer treatment?
Yes. The FDA approved lorlatinib for first-line treatment of adults with metastatic NSCLC whose tumors are ALK-positive.
Is lorlatinib more effective than alectinib?
There is no direct randomized head-to-head trial establishing superiority over alectinib. Lorlatinib has shown exceptional long-term progression-free survival and intracranial control versus crizotinib.
Can lorlatinib be used after alectinib failure?
Yes. Lorlatinib is used in patients with ALK-positive metastatic NSCLC after progression on earlier ALK inhibitors, including alectinib, subject to the applicable product label and clinical judgment.
Will generic lorlatinib be cheaper immediately after patent expiry?
Usually, generic entry reduces price, but the magnitude depends on the number of approved suppliers, payer substitution, launch strategy, and whether Pfizer or an authorized generic remains commercially active.
References
-
Pfizer Inc. (2024). 2024 annual report. Pfizer.
-
Solomon, B. J., Bauer, T. M., Mok, T., Liu, G., Place, T. L., Anrys, B., Van Schil, P. E., et al. (2024). Lorlatinib versus crizotinib in previously untreated advanced ALK-positive non-small-cell lung cancer: 5-year outcomes from the CROWN study. Journal of Clinical Oncology.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Lorbrena (lorlatinib) Orange Book listing. FDA.
-
U.S. Food and Drug Administration. (2024b). Lorbrena (lorlatinib) prescribing information. FDA.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for lorlatinib-related U.S. patents. USPTO.
